|
|
Volumn 78, Issue , 2014, Pages 23-34
|
|
Synthesis and anticancer activities of 4-(4-substituted piperazin)-5,6,7-trialkoxy quinazoline derivatives
|
|
Author keywords
Anticancer; Antiphosphorylation; Cell cycle; ERK1 2; P38; Quinazoline
|
|
Indexed keywords
10L4 [4 (4 CHLOROBENZYL)PIPERAZIN 1 YL] 5,6,7 TRIMETHOXYQUINAZOLINE;
4 (4 BENZYLPIPERAZIN 1 YL) 5,6,7 TRIETHOXYQUINAZOLINE;
4 (4 BENZYLPIPERAZIN 1 YL) 5,6,7 TRIMETHOXYQUINAZOLINE;
4 [4 (4 FLUOROPHENYL)PIPERAZIN 1 YL] 5,6,7 TRIETHOXYQUINAZOLINE;
4 [4 (4 FLUOROPHENYL)PIPERAZIN 1 YL] 5,6,7 TRIMETHOXYQUINAZOLINE;
4 [4 (4 NITROPHENYL)PIPERAZIN 1 YL] 5,6,7 TRIETHOXYQUINAZOLINE;
4 [4 (4 NITROPHENYL)PIPERAZIN 1 YL] 5,6,7 TRIMETHOXYQUINAZOLINE;
5,6,7 TRIETHOXY 4 [4 (3 METHOXYPHENYL)PIPERAZIN 1 YL]QUINAZOLINE;
5,6,7 TRIETHOXY 4 [4 (PHENYLSULFONYL)PIPERAZIN 1 YL]QUINAZOLINE;
5,6,7 TRIETHOXY 4 [4 (PYRIDIN 2 YL)PIPERAZIN 1 YL]QUINAZOLINE;
5,6,7 TRIETHOXY 4 [4 [2 (TRIFLUOROMETHYL)PHENYLSULFONYL]PIPERAZIN 1 YL]QUINAZOLINE;
5,6,7 TRIETHOXY 4 [4 [4 (METHOXYL)PHENYLSULFONYL]PIPERAZIN 1 YL]QUINAZOLINE;
5,6,7 TRIETHOXY 4 [4 [4 (METHYL)PHENYLSULFONYL]PIPERAZIN 1 YL]QUINAZOLINE;
5,6,7 TRIETHOXY 4 [4 [4 (TRIFLUOROMETHYL)PHENYLSULFONYL]PIPERAZIN 1 YL]QUINAZOLINE;
5,6,7 TRIMETHOXY 4 [4 (2 TRIFLUOROMETHYLPHENYLSULFONYL)PIPERAZIN 1 YL]QUINAZOLINE;
5,6,7 TRIMETHOXY 4 [4 (3 METHOXYPHENYL)PIPERAZIN 1 YL]QUINAZOLINE;
5,6,7 TRIMETHOXY 4 [4 (3 MORPHOLINOPROPYL)PIPERAZIN 1 YL)QUINAZOLINE;
5,6,7 TRIMETHOXY 4 [4 (4 FLUOROBENZYL)PIPERAZIN 1 YL]QUINAZOLINE;
5,6,7 TRIMETHOXY 4 [4 (4 METHOXYPHENYLSULFONYL)PIPERAZIN 1 YL]QUINAZOLINE;
5,6,7 TRIMETHOXY 4 [4 (4 METHYLPHENYLSULFONYL)PIPERAZIN 1 YL]QUINAZOLINE;
5,6,7 TRIMETHOXY 4 [4 (4 TRIFLUOROMETHYLPHENYLSULFONYL)PIPERAZIN 1 YL]QUINAZOLINE;
5,6,7 TRIMETHOXY 4 [4 (PHENYLSULFONYL)PIPERAZIN 1 YL]QUINAZOLINE;
5,6,7 TRIMETHOXY 4 [4 (PYRIDIN 2 YL)PIPERAZIN 1 YL]QUINAZOLINE;
5,6,7 TRIMETHOXY N ARYL 4 AMINOQUINAZOLINE;
ANTINEOPLASTIC AGENT;
MITOGEN ACTIVATED PROTEIN KINASE 1;
QUINAZOLINE;
QUINAZOLINE DERIVATIVE;
SYNAPTOPHYSIN;
UNCLASSIFIED DRUG;
MITOGEN ACTIVATED PROTEIN KINASE 3;
MITOGEN ACTIVATED PROTEIN KINASE P38;
ANTINEOPLASTIC ACTIVITY;
ANTIPROLIFERATIVE ACTIVITY;
ARTICLE;
BIOASSAY;
CANCER CELL CULTURE;
CARBON NUCLEAR MAGNETIC RESONANCE;
CELL CYCLE;
CELL PROLIFERATION;
CONTROLLED STUDY;
CRYSTAL STRUCTURE;
DRUG SYNTHESIS;
HUMAN;
HUMAN CELL;
IC 50;
MASS SPECTROMETRY;
PROTEIN PHOSPHORYLATION;
PROTON NUCLEAR MAGNETIC RESONANCE;
X RAY CRYSTALLOGRAPHY;
3T3 CELL LINE;
ANIMAL;
ANTAGONISTS AND INHIBITORS;
CHEMICAL STRUCTURE;
CHEMISTRY;
DOSE RESPONSE;
DRUG EFFECTS;
DRUG SCREENING;
METABOLISM;
MOUSE;
STRUCTURE ACTIVITY RELATION;
SYNTHESIS;
TUMOR CELL CULTURE;
ANIMALS;
ANTINEOPLASTIC AGENTS;
CELL CYCLE;
CELL PROLIFERATION;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG SCREENING ASSAYS, ANTITUMOR;
HUMANS;
MICE;
MITOGEN-ACTIVATED PROTEIN KINASE 1;
MITOGEN-ACTIVATED PROTEIN KINASE 3;
MOLECULAR STRUCTURE;
NIH 3T3 CELLS;
P38 MITOGEN-ACTIVATED PROTEIN KINASES;
QUINAZOLINES;
STRUCTURE-ACTIVITY RELATIONSHIP;
TUMOR CELLS, CULTURED;
|
|
EID: 84897105856
PISSN: 02235234
EISSN: 17683254
Source Type: Journal
DOI: 10.1016/j.ejmech.2014.03.036 Document Type: Article |
|
Times cited : (39)
|
|
References (30)
|
